Novelix Pharmaceuticals share news and announcements
BSE: 536565Healthcare ServicesSmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹62.73.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹170 Cr2,861st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 46.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 11.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 8.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.09
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,524
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Novelix Pharmaceuticals quarterly results
The board met on 13 Aug 2026 to consider quarterly results
Notice filed 10 Aug 2026
Novelix Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Novelix Pharmaceuticals financials, year by year
Annual reports17
- Annual report, year to Mar 2026 (opens in a new tab)7 Sep 2026
- Annual report, year to Mar 2025 (opens in a new tab)26 Aug 2025
- Annual report, 2024 (opens in a new tab)5 Sep 2024
- Annual report, year to Mar 2023 (opens in a new tab)23 Aug 2023
- Annual report, 2022 (opens in a new tab)25 May 2023
12 earlier reports
- Annual report, year to Mar 2021 (opens in a new tab)2 Sep 2021
- Annual report, year to Mar 2020 (opens in a new tab)14 Aug 2020
- Annual report, year to Mar 2019 (opens in a new tab)29 Aug 2019
- Annual report, year to Mar 2018 (opens in a new tab)27 Sep 2018
- Annual report, year to Mar 2017 (opens in a new tab)12 Sep 2017
- Annual report, year to Mar 2016 (opens in a new tab)5 Jul 2016
- Annual report, year to Mar 2015 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2014 (opens in a new tab)9 Sep 2014
- Annual report, year to Mar 2013 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2012 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2011 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2010 (opens in a new tab)Filing day not known
Novelix Pharmaceuticals share news and announcements
605 announcements, routine notices left out, newest first. Page 1 of 13.
Oct 2026
2 Oct · Management
1 Oct · Results
Sep 2026
7 Sep · Meeting
7 Sep · Meeting
Aug 2026
31 Aug · Meeting
29 Aug · Board meeting
25 Aug · Board meeting
Meeting on 29 Aug 2026: annual general meeting20 Aug · Announcement Under Regulation 30 (LODR) - Lease Deed
13 Aug · Results
10 Aug · Board meeting
Meeting on 13 Aug 2026: quarterly results
Jul 2026
13 Jul · Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
10 Jul · Announcement under Regulation 30 (LODR)-Allotment
9 Jul · Board meeting
2 Jul · Results
Jun 2026
4 Jun · Board meeting
2 Jun · Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
1 Jun · Board meeting
Meeting on 4 Jun 2026: preferential issue of shares
May 2026
31 May · Announcement Under Regulation 30 (LODR)- Authorization Of Kmps Under Regulation 30(5) SEBI (LODR) Regulations, 2015
30 May · Announcement under Regulation 30 (LODR)-Allotment
29 May · Results
25 May · Board meeting
Meeting on 29 May 2026: audited results, preferential issue of shares and quarterly results
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.
- 1 Apr 2026Board or managers changeddown 3.26%−5.2 pts vs Nifty 500market median 0.0% · five sessions −4.6% (−12.5 pts vs Nifty 500) · volume 10.1× usual · The announcement (opens in a new tab)
- 17 Nov 2025Board or managers changedup 5.00%+4.5 pts vs Nifty 500market median 0.0% · five sessions −5.5% (−5.3 pts vs Nifty 500) · volume 0.6× usual · The announcement (opens in a new tab)
- 15 Apr 2025Board or managers changed–market median 0.0% · five sessions +5.0% (−7.0 pts vs Nifty 500) · volume 13.5× usual · The announcement (opens in a new tab)
- 17 Feb 2025Board or managers changed0.00%+3.4 pts vs Nifty 500market median 0.0% · five sessions +5.0% (+10.0 pts vs Nifty 500) · volume 5.3× usual · The announcement (opens in a new tab)
- 11 Aug 2023Board or managers changed–market median 0.0% · five sessions −13.8% (−13.2 pts vs Nifty 500) · volume 0.3× usual · The announcement (opens in a new tab)
- 1 Apr 2016Board or managers changeddown 4.96%−6.7 pts vs Nifty 500market median 0.0% · five sessions −7.7% (−7.9 pts vs Nifty 500) · volume 0.0× usual
Figures filed again
Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Net profit | Quarter to Jun 2022 | Standalone | −0.06 | −0.04 | +37.0% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Total comprehensive income | Quarter to Jun 2022 | Standalone | −0.06 | −0.04 | +37.0% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Employee costs | Quarter to Jun 2022 | Standalone | 0.06 | 0.07 | +4.6% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Other expenses | Quarter to Jun 2022 | Standalone | 0.07 | 0.07 | −4.2% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Tax | Quarter to Jun 2022 | Standalone | 0.00 | 0.00 | −200.0% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Segment profit before tax and finance costs | Quarter to Jun 2022 | Standalone | −0.06 | −0.06 | 0.0% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Deferred tax | Quarter to Jun 2022 | Standalone | 0.00 | 0.00 | −200.0% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Segment profit before tax | Quarter to Jun 2022 | Standalone | −0.06 | −0.06 | 0.0% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Net profit from continuing businesses | Quarter to Jun 2022 | Standalone | −0.06 | −0.06 | +6.9% | 6 Sep 2022 (opens in a new tab) | 25 Nov 2022 (opens in a new tab) |
| Total comprehensive income | Quarter to Jun 2019 | Standalone | 0.01 | 0.01 | +1.2% | 17 Aug 2019 (opens in a new tab) | 20 Nov 2019 (opens in a new tab) |